

# Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis

Yu-Hao Lin,<sup>1</sup> Hong Ma,<sup>1,2</sup> Li-Zhen Dai,<sup>1</sup> Chen-Shi Lin,<sup>2</sup> Yan-Ling Huang,<sup>2</sup> Shu-Yuan Liu<sup>2</sup>

Correspondence to Professor Hong Ma; mah-169@163.com

Word count: 3533

## Author affiliations

<sup>1</sup>Department of Endocrinology, The Third Clinical Medical College of Fujian Medical University, Xiamen, Fujian, China.

<sup>2</sup>Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China.

Authors' information: names and e-mail addresses:

Yu-Hao Lin: tzlanyuhao@163.com

Hong Ma: mah-169@163.com

Li-Zhen Dai: 825146078@qq.com

Chen-Shi Lin: 24520211154539@stu.xmu.edu.cn

Yan-Ling Huang: xmhuangyanling@163.com

Shu-Yuan Liu: lsy2561@163.com

## **ABSTRACT**

### **Objective**

To compare the efficacy and safety between and within glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) in overweight or obese adults with or without diabetes mellitus.

### **Methods**

PubMed, ISI Web of Science, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) database were comprehensively searched to identify randomised controlled trials (RCTs) of effects of GLP-1RAs and SGLT-2is in overweight or obese participants from inception to Jan 16, 2022. The efficacy outcomes were the changes of body weight, glycemic control and blood pressure. The safety outcomes were the serious adverse events and discontinuation due to adverse events. The mean differences (MDs), odds ratios (ORs), 95% credible intervals (95% CI), the surface under the cumulative ranking (SUCRA) were evaluated for each outcome by network meta-analysis.

### **Results**

Sixty one RCTs were included in our analysis. Both GLP-1RAs and SGLT-2is conferred greater extents in body weight reduction, achieving at least 5% weight loss, HbA1c and fasting plasma glucose decrease compared with placebo. GLP-1RAs was superior to SGLT-2is in HbA1c reduction (MD: -0.39%, 95% CI: -0.70 to -0.08). GLP-1RAs had high risk of adverse events, while SGLT-2is were relatively safe. Based on intraclass comparison, semaglutide 2.4mg was the most efficacious agent in losing body weight (MD: -11.51kg, 95% CI: -12.83 to -10.21, SUCRA: 0.99), decreasing HbA1c (MD: -1.49%, 95% CI: -2.07 to -0.92, SUCRA: 0.93), fasting plasma glucose (MD: -2.15mmol/L, 95% CI: -2.83 to -1.59, SUCRA: 0.92), reducing

systolic blood pressure (MD: -4.89mmHg, 95% CI: -6.04 to -3.71, SUCRA: 0.96), diastolic blood pressure (MD: -1.59mmHg, 95% CI: -2.37 to -0.86) while it was associated with high risk of adverse events.

## **Conclusions**

Semaglutide 2.4mg showed greatest effects on losing body weight, controlling glycemic level and reducing blood pressure while it was associated with high risk of adverse events.

**Keywords:** Glucagon-Like Peptide 1, Sodium-Glucose Transporter 2 Inhibitors, overweight, obesity, diabetes

## **ARTICLE SUMMARY**

### **Strengths and limitations of this study**

- ▶ Different types of GLP-1RAs and SGLT-2is in overweight/obese patients with or without diabetes mellitus were compared and analyzed in the study.
- ▶ In the absence of direct ‘head-to-head’ comparisons of GLP-1RAs and SGLT-2is in overweight or obese adults with or without diabetes mellitus, network meta-analysis was performed to compare the efficacy and safety of the drugs.
- ▶ The efficacy and safety between different dose of liraglutide and semaglutide was compared and analyzed in the study.
- ▶ Limitation of this study was that the numbers of RCTs included were few in some comparisons.

## INTRODUCTION

The World Health Organization (WHO) claimed that obesity has become a major public health challenge of the 21st century<sup>1</sup>. Obesity can cause considerable harm to affect individuals notably, including physical disabilities, psychological problems, increasing the risk of expanding sets of chronic diseases, such as diabetes mellitus, cardiovascular diseases (CVD), certain cancers and depression<sup>2,3</sup>. In addition, obesity is associated with higher all-cause mortality<sup>4</sup>, resulting in approximately 4.7 million premature deaths per year<sup>5</sup>.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and Sodium-glucose co-transporter 2 inhibitors (SGLT-2is) are both the novel glucose-lowering agents. These two categories of drugs can not only improve glycemic control, but also reduce body weight and decrease the risk of cardiovascular disease by different mechanisms.

GLP-1RAs reduce the body weight by reducing the appetite, increasing the satiety, slowing the release of food from the stomach; and they decrease glucose level by inhibiting intestinal glucose uptake and gastric emptying, stimulating insulin and inhibiting glucagon secretion physiologically<sup>6,7</sup>. Whereas, sodium-glucose co-transporter 2 (SGLT-2) is a functional protein, which can promote filtered glucose and sodium to reabsorb in the proximal tubule of the kidneys. SGLT-2is increased glycosuria and natriuresis by inhibiting the activity of SGLT-2 to achieve these beneficial effects<sup>8</sup>.

As we know, both GLP-1RAs and SGLT-2is are recommend as medication options in type 2 diabetes mellitus patients with overweight or obesity by the American Diabetes Association (ADA). Further, the US Food and Drug Administration (FDA) has approved two kinds of GLP-1RAs: liraglutide 3.0 mg and semaglutide 2.4 mg for obese or overweight individuals with at least one weight-related comorbidity<sup>9</sup>.

Recently, there are many randomised controlled trials (RCTs) comparing GLP-1RAs or SGLT-2is with placebo in overweight/obese patients with or without diabetes. But, the directly comparisons between GLP-1RAs and SGLT-2is is few. In the absence of direct ‘head-to-head’ data, network meta-analysis is considered as the methodology of choice to obtain a relatively scientific evaluation of the results<sup>10</sup>.

Thus, we conducted a systematic review and network meta-analysis to estimate the difference of the efficacy and safety between and within GLP-1RAs and SGLT-2is treatments in overweight or obesity patients with or without diabetes by synthesizing the direct and indirect data of RCTs. Different GLP-1RAs and SGLT-2is and different dosage of liraglutide and semaglutide were separately analyzed including exenatide 10ug, dulaglutide 1.5mg, liraglutide 1.8mg, liraglutide 3.0mg, semaglutide 1.0mg, semaglutide 2.4mg, canagliflozin 300mg, dapagliflozin 10mg and empagliflozin 10mg to explore for potential differences among individual GLP-1RAs and SGLT-2is. The aim of this study was to provide useful insights to support clinical decision-making.

## **METHODS**

This systematic review and network meta-analysis had been registered on PROSPERO (No. CRD42021258103). The methods and results of this review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Network Meta-Analyses<sup>11</sup>.

### **Data sources and search strategy**

A comprehensive search of PubMed, ISI Web of Science, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) was conducted in each database from inception to Jan 16, 2022 for RCTs in any language. The search strategy used

Medical SubjectHeadings and relevant text words that consisted of terms relating to “Glucagon-Like Peptide 1”, “Sodium-Glucose Transporter 2 Inhibitors”, “obesity” and “overweight”. Full search strategy is presented in online Supplemental Table 1. In addition, other relevantly published and unpublished trials were conducted by manual search.

### **Study selection and eligibility criteria**

Two authors independently selected the studies that followed the PICO (population, intervention, comparator, outcome) framework, with any discrepancies resolved through a third author. Studies were deemed eligible if they: (a) design of RCTs; (b) participants were overweight ( $BMI \geq 25 \text{ kg/m}^2$ , Asian  $\geq 23 \text{ kg/m}^2$ ) or obesity ( $BMI \geq 30 \text{ kg/m}^2$ ) adults ( $\geq 18$  years) ; (c) interventions were long-acting, short-acting GLP-1RAs or SGLT-2is; (d) compared intervention(s) with placebo or GLP-1RAs or SGLT-2is; (e) outcomes considered were at least one of the following: changes in body weight, proportion of participants reaching at least 5% weight loss, hemoglobin A1c, fasting plasma glucose (FPG), systolic blood pressure (SBP), diastolic blood pressure (DBP), serious adverse events (SAE) or discontinuation due to adverse events. Further, the RCTs with the results presented on ClinicalTrials.gov were also included. Studies were excluded if they: (a) patients with renal transplant, undergoing bariatric surgery, clozapine- and olanzapine- treated schizophrenia overweight; (b) recruited single gender populations (e.g. entirely females); (c) duration of interventions less than 12 weeks; (d) medications that have been withdrawn from the market.

### **Data Extraction**

Two authors independently extracted data using a standardized pre-defined spreadsheet from each included study; discrepancies were resolved by a third author. The following parameters were extracted: first author name; year of publication;

clinicaltrials.gov trial number or UMIN-CTR search clinical number; intervention(s) and comparator(s); duration of follow-up; baseline characteristics of participants and background therapy. The data of number of participants, mean differences (MDs), standard deviation were extracted for continuous outcomes, total number of participants; numbers of participants with events were extracted for dichotomous outcomes. If standard deviation data were not reported, standard error or 95% credible intervals was used to calculate it. For trials assessing more than one dose of dulaglutide, only data for the dosage of 1.5mg were included. If the same population were involved in more than one published studies, only the primary study was considered.

### **Risk of bias**

The Cochrane Collaboration Risk of Bias 2.0 tool was used to assess the risk of bias of individual studies in regard to the following aspects: randomization process, intended interventions, missing outcome data, measurement of the outcome and selection of the reported result<sup>12</sup>. And the quality of evidence for the network meta-analysis was evaluated based on GRADE approach<sup>13</sup>. Publication bias was assessed with comparison-adjusted funnel plots<sup>14</sup>. Any discrepancies were resolved by a third author.

### **Statistical analysis**

In this study, we calculated MDs for continuous outcomes and odds ratios (ORs) for dichotomous outcomes, along with 95% credible intervals (95% CI) for efficacy and safety outcomes. Direct pairwise meta-analysis for treatment comparisons was performed using DerSimonian-Laird random-effects model<sup>15</sup>. Heterogeneity was assessed with the  $I^2$  and  $I^2 > 50\%$  indicated substantial heterogeneity<sup>16</sup>. Based on Markov-chain Monte Carlo method, we performed random-effects Bayesian network

meta-analyses to analyze direct and indirect comparisons of different treatments<sup>17</sup>. And all treatment contrasts were assumed to have the same heterogeneity variance. The ranking probabilities of all treatments on efficacy and safety outcomes were displayed on their surface under the cumulative ranking (SUCRA) probabilities. The larger the SUCRA value is, the better is the rank of the treatment for outcomes<sup>18</sup>. In each closed loop, inconsistency of the model was assessed by the node splitting method. Sensitivity analysis was performed to assess the robustness of the findings. All two-sided *p*-values of <0.05 was considered as statistically significant. Statistical analyses were conducted using R with “gemtc” and “meta” packages, Stata 16 MP were used for comparison-adjusted funnel plots.

## RESULTS

We identified 12812 trials using the search strategy, and 7346 duplicates were eliminated. After 5466 trails were screening for titles and abstracts, 736 trials were received for full-text screening. Finally 61 RCTs with 17281 participants were included for the analyses. Details of trials selection were showed in Figure 1. The available networks of evidence were displayed in Figure 2. In 61 RCTs, 60 RCTs were parallel design, except 1 RCT was across-over design; and 56 RCTs were blinded design, remaining 5 RCTs were open-label design. The participants of 35 RCTs were reported in overweight/obese patients with diabetes, whereas 20 RCTs were conducted in overweight/obese patients without diabetes, remaining 6 RCTs performed in overweight/obese patients with or without diabetes. The duration of all RCTs ranged from 12 weeks to 72 weeks, with the median of 24 weeks (interquartile range [IQR] 16 weeks to 36 weeks).



The median of average age of patients across RCTs was 54.1 years (range, 24.0-68.0 years). Patients' median of average BMI was 33.6 kg/m<sup>2</sup> (range, 27.3-40.1 kg/m<sup>2</sup>), median of average body weight was 96.4 kg (range, 68.0-118.7 kg). The mean duration of diabetes was 8.72 years (SD 4.93 years), mean of baseline HbA1c was 7.92 % (SD 0.54 %) in participants with diabetes. In most RCTs, participants received lifestyle modification, including hypocaloric diet and regular physical activity. The characteristics of included RCTs were summarized in online Supplemental Table 2.

### **Risk of bias**

Among 61 RCTs, 47 RCTs with low risk, 2 RCTs with high risk, and 12 RCTs were judged to some concerns in overall risk of bias (online Supplemental Table 3). The quality of evidence was low to moderate in most comparisons for body weight and achieving at least 5% weight loss, and the confidence downgraded mainly due to study limitation, inconsistency, indirectness and imprecision (online Supplemental Table 4). Further, comparison-adjusted funnel plots were relatively symmetric and did not suggest the presence of publication bias (online Supplemental Figure 1).

### **Body Weight**

With respect to the change in body weight, 56 RCTs were analyzed. In direct pairwise meta-analyses, compared with placebo, reductions in body weight were observed in GLP-1RAs and SGLT-2is, range from -1.47kg to -11.47kg (online Supplemental Figure 3). Results of network meta-analysis demonstrated that both GLP-1RAs and SGLT-2is had effects on body weight reduction, and these two agents conferred similar body weight reductions (online Supplemental Table 5). Compared to placebo, semaglutide 2.4mg (MD: -11.51kg, 95% CI: -12.83 to -10.21, SUCRA: 0.99) showed greatest reduction in body weight, followed by semaglutide 1.0mg (MD: -5.67kg, 95% CI: -7.84 to -3.52, SUCRA: 0.86), liraglutide 3.0mg (MD: -4.65kg, 95% CI: -5.60 to -

3.69, SUCRA: 0.79). Liraglutide 1.8mg, exenatide 10ug, dulaglutide 1.5mg and dapagliflozin 10mg reduced body weight from -3.14kg to -1.28kg. Canagliflozin 300mg and empagliflozin 10mg had modest effects in body weight reduction. Compared with other medications, semaglutide 2.4mg showed greater benefits in body weight, ranged from -10.23kg to -5.84kg (Figure 3, online Supplemental Figure 2).

### **Reaching $\geq 5\%$ weight loss**

With respect to reaching at least 5% weight loss, 24 RCTs were analyzed. Due to limited RCTs, outcome of reaching at least 5% weight loss were not analyzed in dulaglutide 1.5mg and empagliflozin 10mg. Pairwise meta-analysis results are presented in online Supplemental Figure 3. Results of network meta-analyses demonstrated that compared with placebo, both GLP-1RAs and SGLT-2is was associated with higher odds of reaching at least 5% weight loss. While no notable differences were evident between GLP-1RAs and SGLT-2is. Compared to placebo, semaglutide 2.4mg (OR: 10.88, 95% CI: 6.69 to 18.39, SUCRA: 0.97) was associated with the highest odds in reaching weight reductions of at least 5%, followed by semaglutide 1.0mg (OR: 7.02, 95% CI: 3.25 to 16.50, SUCRA: 0.80), liraglutide 3.0mg (OR: 4.90, 95% CI: 3.37 to 7.13, SUCRA: 0.64), liraglutide 1.8mg (OR: 3.81, 95% CI: 2.31 to 6.70, SUCRA: 0.49), canagliflozin 300mg (OR: 2.70, 95% CI: 1.19 to 6.40, SUCRA: 0.51), no difference was found in exenatide 10ug. Based on intraclass comparisons, semaglutide 2.4mg was superior to liraglutide 3.0mg, liraglutide 1.8mg, canagliflozin 300mg and exenatide 10ug; semaglutide 1.0mg was superior to exenatide 10ug (Figure 3, online Supplemental Figure 2).

### **Glycemic Control**

Outcomes of HbA1c were analyzed in diabetic patients with 35 RCTs. Direct pairwise

meta-analyses showed that GLP-1RAs and SGLT-2is were associated with reduction in HbA1c compared with placebo (online Supplemental Figure 3). Network meta-analysis results showed that both GLP-1RAs and SGLT-2is were associated with greater extent in HbA1c reduction compared with placebo. Further, GLP-1RAs was superior to SGLT-2is (MD: -0.39%, 95% CI: -0.70 to -0.08) in HbA1c reduction (online Supplemental Table 5). Compared with placebo, semaglutide 2.4mg was the most efficacy agents (MD: -1.49%, 95% CI: -2.07 to -0.92, SUCRA: 0.93), followed by semaglutide 1.0mg (MD: -1.38%, 95% CI: -1.83 to -0.96, SUCRA: 0.89) and dulaglutide 1.5mg (MD: -1.11%, 95% CI: -1.44 to -0.79, SUCRA: 0.75). Liraglutide 3.0mg, exenatide 10ug, liraglutide 1.8mg, canagliflozin 300mg and dapagliflozin 10mg were conferred HbA1c reductions ranging from -0.98% to -0.48% (Figure 4, online Supplemental Figure 2). Outcomes of fasting plasma glucose were also analyzed in diabetic patients with 30 RCTs. Pairwise meta-analysis results were presented in online Supplemental Figure 3. Network meta-analysis results showed that both of GLP-1RAs and SGLT-2is showed greater efficacy in fasting plasma glucose reduction compare with placebo. While no notable differences were found between GLP-1RAs and SGLT-2is. The most efficacy in a mean fasting plasma glucose reduction was semaglutide 2.4mg (MD: -2.15mmol/L, 95% CI: -2.83 to -1.59, SUCRA: 0.92), followed by semaglutide 1.0mg (MD: -2.01mmol/L, 95% CI: -2.67 to -1.54, SUCRA: 0.84) and liraglutide 3.0mg (MD: -1.86mmol/L, 95% CI: -2.45 to -1.26, SUCRA: 0.75) compared with placebo. Dulaglutide 1.5mg, liraglutide 1.8mg, exenatide 10ug, canagliflozin 300mg, dapagliflozin 10mg and empagliflozin 10mg were conferred fasting plasma glucose reductions ranging from -1.79mmol/L to -0.81mmol/L (Figure 4, online Supplemental Figure 2).

## **Blood Pressure**

## Systolic blood pressure

Thirty seven RCTs were included in the analysis of systolic blood pressure. Pairwise meta-analysis results were presented in online Supplemental Figure 3. In network meta-analysis, GLP-1RAs had effects on systolic blood pressure decrease, while SGLT-2is had modest effects. Compared with placebo, semaglutide 2.4mg (MD: -4.89mmHg, 95% CI: -6.04 to -3.71, SUCRA: 0.96), exenatide 10ug (MD: -3.86mmHg, 95% CI: -6.29 to -1.47, SUCRA: 0.78) and semaglutide 1.0mg (MD: -3.25mmHg, 95% CI: -5.46 to -1.04, SUCRA: 0.68) ranked as the top three in systolic blood pressure reduction, followed by liraglutide 1.8mg and liraglutide 3.0mg. However, dulaglutide 1.5mg, canagliflozin 300mg, dapagliflozin 300mg and empagliflozin 10mg had a neutral effect. Further, based on intraclass comparison, semaglutide 2.4mg was more efficacious than liraglutide 3.0mg, liraglutide 1.8mg, dulaglutide 1.5mg, canagliflozin 300mg and dapagliflozin 10mg in reducing systolic blood pressure, while no significant differences were found between other individual GLP-1RAs and SGLT-2is (Figure 5, online Supplemental Figure 2).

## Diastolic blood pressure

Thirty four RCTs were included in the analysis of diastolic blood pressure. Data on diastolic blood pressure of empagliflozin 10mg were not available because of limited RCTs. Pairwise meta-analysis results were presented in online Supplemental Figure 3. In network meta-analysis, GLP-1RAs significantly reduced diastolic blood pressure in comparison with placebo, while SGLT-2is had neutral effects in diastolic blood pressure reduction. In addition, semaglutide 2.4mg (MD: -1.59mmHg, 95% CI: -2.37 to -0.86) had greater extent in diastolic blood pressure reduction, while SGLT-2is and other kinds of GLP-1RAs had neutral effects compared with placebo. Further, based on intraclass comparison, semaglutide 2.4mg was more effective than liraglutide

3.0mg, liraglutide 1.8mg, semaglutide 1.0mg and dapagliflozin 10mg in diastolic blood pressure reduction, while no significant differences were found between other individual GLP-1RAs and SGLT-2is (Figure 5, online Supplemental Figure 2).

### **Adverse event outcomes**

#### **Serious adverse events**

Pairwise meta-analysis results showed higher odds of serious adverse events for semaglutide 2.4mg and liraglutide 3.0mg compare with placebo (online Supplemental Figure 3). In network meta-analysis, compared with placebo, GLP-1RAs was associated with higher risk of serious adverse events, while SGLT-2is had no significant difference. Semaglutide 2.4mg (OR: 1.42, 95% CI: 1.02 to 1.99) increased the risk of serious adverse events in comparison with placebo. Whereas, no differences of serious adverse events were found in other kinds of GLP-1Ras and SGLT-2is (Figure 6, online Supplemental Figure 2).

#### **Discontinuation due to adverse events**

Pairwise meta-analysis results showed that compared with placebo, the majority of GLP-1RAs had higher odds of discontinuation due to adverse events, but not for dulaglutide 1.5mg (online Supplemental Figure 3). In network meta-analysis, compared with placebo, GLP-1RAs was associated with higher risk of discontinuation due to adverse events, while SGLT-2is had no significant difference. In addition, exenatide 10ug (OR: 2.96, 95% CI: 1.79 to 4.99), liraglutide 3.0mg (OR: 2.88, 95% CI: 1.90 to 4.24), semaglutide 2.4mg (OR: 1.88, 95% CI: 1.12 to 2.99) was ranked top three in the risk of discontinuation due to adverse events, while no differences were found in dulaglutide 1.5mg, semaglutide 1.0mg, canagliflozin 300mg, dapagliflozin 10mg and empagliflozin 10mg (Figure 6, online Supplemental Figure 2).

### **Sensitive analysis**

Sensitivity analysis was performed to assess the body weight reduction that restricted to RCTs at low risk of bias. In sensitivity analysis, compared with placebo, mostly results were consistently with outcomes of main analysis. Compared with placebo, exenatide 10ug showed greater reduced body weight in the main analysis, while in the sensitive analysis exenatide 10ug had neutral effects in body weight reduction (online Supplemental Table 6).

## **DISCUSSION**

Both GLP-1RAs and SGLT-2is were antidiabetic agents; they also had potent effects on body weight reduction. Further, liraglutide 3.0 mg and semaglutide 2.4 mg was approved for obese or overweight individuals with at least one weight-related comorbidity by FDA<sup>9</sup>. Thus, we conducted a network meta-analysis in overweight or obesity patients with or without diabetes to provide evidences of efficacy and safety difference in GLP-1RAs (including exenatide 10ug, liraglutide 1.8mg, liraglutide 3.0mg, semaglutide 1.0mg, semaglutide 2.4mg and dulaglutide 1.5mg) and SGLT-2is (including canagliflozin 300mg, dapagliflozin 10mg and empagliflozin 10mg).

Results of our network meta-analyses demonstrated that GLP-1RAs and SGLT-2is conferred similar body weight reductions. Based on intraclass comparisons, semaglutide 2.4mg, semaglutide 1.0mg and liraglutide 3.0mg were the most efficacious agents; dapagliflozin 10mg was the most efficacy agents among SGLT-2is. Recently a network meta-analysis of Palmer et al. found that GLP-1RAs was inferior to SGLT-2is in body weight reduction in patients with T2DM<sup>19</sup>. The different results were probably due to differences in the eligible participants. Palmer et al. performed analysis in patients with T2DM, while in our network meta-analysis, the participants analyzed in the studies included overweight or obese patients with or without diabetes. For glycemic control, the analysis of Palmer et al. indicated that GLP-1RAs was

superior to SGLT-2is in HbA1c reduction in patients with T2DM. Our network meta-analysis showed that both GLP-1RAs and SGLT-2is were associated with greater decrease in HbA1c and fasting plasma glucose in overweight or obese patients with diabetes compared with placebo. And GLP-1RAs was superior to SGLT-2is in HbA1c reduction which was consistent with Palmer's result. In addition, semaglutide 2.4mg was the most efficacious agent among active treatments in glycemic control in our analysis.

One previous network meta-analysis showed that both GLP-1RAs and SGLT-2is had benefits in systolic blood pressure reduction and semaglutide had greater extent efficacy than dulaglutide<sup>20</sup> in patients with T2DM. The authors also found that dulaglutide was more efficacious than exenatide and semaglutide in diastolic blood pressure reduction. In our network meta-analysis, we analyzed RCTs with kinds of GLP-1RAs and SGLT-2is in overweight or obese patients with or without diabetes; Results demonstrated that semaglutide 2.4mg was associated with the greatest decrease in systolic blood pressure, followed by exenatide 10ug and semaglutide 1.0mg, while SGLT-2is had neutral effects. In addition, semaglutide 2.4mg was more efficacy than dulaglutide 1.5mg in systolic blood pressure. In diastolic blood pressure reduction, only semaglutide 2.4mg had significant efficacy, and no difference was found between semaglutide 2.4mg and dulaglutide 1.5mg.

Since the different side effects in GLP-1RAs and SGLT-2is, serious adverse events and discontinuation due to adverse events was considered to assess the safety of these drugs. Results of our network analysis indicated that GLP-1RAs was associated with high risk of serious adverse events and discontinuation due to adverse events, SGLT-2is had better tolerability. Semaglutide 2.4mg conferred highest risk of serious adverse events. Exenatide 10ug, liraglutide 3.0mg and semaglutide 2.4mg was ranked

top three in the risk of discontinuation due to adverse events.

There are several strengths in our network meta-analysis. We utilized a comprehensive literature search, stringent inclusion and exclusion criteria to identify eligible studies, used RoB 2.0 and GRADE method to assess the risk of bias and evaluate confidence in effect estimates. Further, we included RCTs with different dosages of liraglutide and semaglutide, and compared the distinction among them. Moreover, not only the difference between GLP-1RAs and SGLT-2is was analyzed, but also intraclass differences between individual of GLP-1RAs and SGLT-2is were illustrated. Certain limitations should be acknowledged. First, with few studies on directly comparisons between active agents, our analysis were mostly based on indirect comparisons. Second, one of the inherent limitation of all meta-analyses is that the presence of a certain degree of clinical heterogeneity in terms of various factors-i.e., patient baseline characteristics, cointerventions, background therapy and outcome assessment. Thirdly, with the outcome of achieving at least 5% weight loss, our analysis found that semaglutide 2.4mg had similarly effects compared with semaglutide 1.0mg. This finding was different with the result of RCT study STEP 2<sup>21</sup> due to limited “head-to-head” data in our analysis. Another factor to be considered is that in some comparison, numbers of RCTs included in the analysis were few. Recently, ADA recommend GL-1RAs and SGLT-2is as appropriate initial therapy for individuals with type 2 diabetes at high risk for atherosclerotic cardiovascular disease (ASCVD), heart failure, and/or chronic kidney disease. Obesity is strongly and continuously associated with ASCVD in the adults<sup>22</sup>. Reducing body weight can improve cardiometabolic risk factors and health-related quality of life in overweight or obese patients<sup>23 24</sup>. In clinical practice, individualized choice of optimal treatments such as efficacy, safety, medication adherence, treatment costs and medication



accessibility should be considered.

## CONCLUSION

In conclusion, both GLP-1RAs and SGLT-2is showed great reduction in body weight, HbA1c and fasting plasma glucose in overweight or obesity patients with or without diabetes. Across individual agents, semaglutide 2.4mg showed greatest effects on losing body weight, controlling glycemic levels and reducing blood pressure, while it was associated with highest risk of adverse events. SGLT-2is had modestly effects on body weight and glucose level, but they had better tolerability. This network meta-analysis provided evidences of efficacy and safety differences of GLP-1RAs and SGLT-2is in overweight or obesity adults with or without diabetes to guide the clinical practice.

## Acknowledgements

We would like to thank Natural Science Foundation of Fujian Province, China for funding this work.

## Author Contributions

The first author (YL) formulated the search strategy, selected studies for inclusion, extracted the data for outcomes, analyzed the data with R and drafted the manuscript. HM was responsible for the revision of the manuscript. LD was responsible for selected studies for inclusion and extracted the data for outcomes. CL was responsible for the solution of any discrepancies. YH and SL were responsible for the oversight of study.

## Funding

This work was supported by the Natural Science Foundation of Fujian Province, China (Grant No.2021J011337).

## Competing interests

None declared.

## Patient consent for publication

Not required.

## Provenance and peer review

Not commissioned; externally peer reviewed.

## Data availability statement

Data are available in a public, open access repository. All data relevant to the study are included in the article or uploaded as supplemental information.

## Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iD

Hong Ma <http://orcid.org/0000-0003-4415-694X>

Yu-Hao Lin <http://orcid.org/0000-0002-8244-8495>

Li-Zhen Dai <http://orcid.org/0000-0001-6194-7984>

Chen-Shi Lin <http://orcid.org/0000-0001-9412-8934>

Yan-Ling Huang <http://orcid.org/0000-0002-3347-2173>

Shu-Yuan Liu <http://orcid.org/0000-0003-3419-4782>

## REFERENCE

1. World Health Organization (WHO). Obesity, retrieved on 10 September 2017.  
<http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity>.
2. Blüher M. Obesity: global epidemiology and pathogenesis. *Nat Rev Endocrinol* 2019;15(5):288-98.
3. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer--  
Viewpoint of the IARC Working Group. *N Engl J Med* 2016;375(8):794-8.
4. Global BMIMC, Di Angelantonio E, Bhupathiraju Sh N, et al. Body-mass index  
and all-cause mortality: individual-participant-data meta-analysis of 239  
prospective studies in four continents. *Lancet* 2016;388(10046):776-86.
5. Global, regional, and national age-sex-specific mortality for 282 causes of death  
in 195 countries and territories, 1980-2017: a systematic analysis for the Global  
Burden of Disease Study 2017. *Lancet* 2018;392(10159):1736-88.
6. Smits MM, Tonneijck L, Muskiet MH, et al. Gastrointestinal actions of  
glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.  
*Diabetes Obes Metab* 2016;18(3):224-35.
7. Ard J, Fitch A, Fruh S, et al. Weight Loss and Maintenance Related to the  
Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. *Adv Ther*  
2021;38(6):2821-39.
8. Ferrannini E. Sodium-Glucose Co-transporters and Their Inhibition: Clinical  
Physiology. *Cell Metab* 2017;26(1):27-38.
9. Mullard A. New hope for anti-obesity drugs. *Nat Rev Drug Discov*  
2021;20(8):575. doi: 10.1038/d41573-021-00109-4 [published Online First:  
2021/06/16]
10. Zeng W, Guo Y, Wu G, et al. Mirror therapy for motor function of the upper

- extremity in patients with stroke: A meta-analysis. *J Rehabil Med* 2018;50(1):8-15.
11. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162(11):777-84.
12. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *Bmj* 2019;366:l4898.
13. Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. *PLoS One* 2014;9(7):e99682.
14. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. *Res Synth Methods* 2012;3(2):161-76.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7(3):177-88.
16. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *Bmj* 2003;327(7414):557-60.
17. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med* 2004;23(20):3105-24.
18. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011;64(2):163-71.
19. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised

- controlled trials. *Bmj* 2021;372:m4573.
20. Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. *Diabetes Obes Metab* 2021;23(9):2116-24.
  21. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet* 2021;397(10278):971-84.
  22. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;42(34):3227-337.
  23. Wing RR, Espeland MA, Clark JM, et al. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. *Diabetes Care* 2016;39(8):1345-55.
  24. Slagter SN, van Vliet-Ostaptchouk JV, van Beek AP, et al. Health-Related Quality of Life in Relation to Obesity Grade, Type 2 Diabetes, Metabolic Syndrome and Inflammation. *PLoS One* 2015;10(10):e0140599.

**Figure 1.** Summary of study search and selection.

**Figure 2.** The network diagrams of all eligible comparisons for the primary outcomes of efficacy and safety. (A) Body weight; (B) Achieving  $\geq 5\%$  weight loss; (C) Systolic blood pressure; (D) Diastolic blood pressure; (E) HbA1c; (F) Fasting plasma glucose; (G) Serious adverse events; (H) Discontinuation due to adverse events. CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; Exe, exenatide; DUL, dulaglutide; LIR, liraglutide; SEM, semaglutide.

**Figure 3.** Network meta-analysis results among active treatment. (A) body weight (kg); (B) achieving  $\geq 5\%$  weight loss (%). MD, mean difference; OR, odds ratio; 95% CI, 95% credible interval; CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; Exe, exenatide; DUL, dulaglutide; LIR, liraglutide; SEM, semaglutide.

**Figure 4.** Network meta-analysis results among active treatment. (A) HbA1c (%); (B) Fasting plasma glucose (mmol/L). MD, mean difference; 95% CI, 95% credible interval; CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; Exe, exenatide; DUL, dulaglutide; LIR, liraglutide; SEM, semaglutide.

**Figure 5.** Network meta-analysis results among active treatment. (A) Systolic blood pressure (mmHg); (B) Diastolic blood pressure (mmHg). MD, mean difference; 95% CI, 95% credible interval; CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; Exe, exenatide; DUL, dulaglutide; LIR, liraglutide; SEM, semaglutide.

**Figure 6.** Network meta-analysis results among active treatment. (A) Serious adverse events; (B) Discontinuation due to adverse events. OR, odds ratio; 95% CI, 95% confidence interval; CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; Exe, exenatide; DUL, dulaglutide; LIR, liraglutide; SEM, semaglutide.

**12812** Records identified by electronic database search

**2174** Pubmed

**3224** ISI Web of Science

**3091** Embase

**4323** Cochrane (ICTRP: **487**,  
CT.gov: **327**,CINAHL: **18%**)

**13** Records identified through manual search

**7346** of duplicate records excluded

**5466** of records for titles and abstracts screen

**4370** Excluded

**2523** Review articles or meeting abstract or editorials

**713** Observational studies

**378** Animal studies

**756** Population or interventions not of interest

**736** of full-text articles assessed for eligibility

**675** Excluded

**226** Polled, subgroup or post hoc analysis of already included trial


**106** Duration less than 12 weeks

**189** Body mass index not reported in eligible criteria


**154** Not reported interest outcomes

**61** Randomised clinical trials included in the systematic review and network meta-analysis


A




B




C




D




# E




F



G




H





A



B

